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Abstract
Background: The aim of the study was to evaluate the occurrence, 
duration and impact of time delays to primary percutaneous coronary 
intervention (pPCI) in ST-segment elevation myocardial infarction 
(STEMI).
Methods: A total of 357 consecutive STEMI patients enrolled in 
the prospective Special Program University Medicine ACS (SPUM-
ACS) cohort were included. In order to identify the causes behind a 
possible treatment delay, we constructed four different time points 
which included: 1) symptom onset to hospital arrival, 2) hospital ar-
rival to arrival in the catheterization laboratory, 3) hospital arrival to 
first balloon inflation, and 4) time from arrival in the catheterization 
laboratory to first balloon inflation in addition to total ischemic time. 
Patients were stratified according to a delay > 3 h, > 30 min, > 90 min 
and > 1 h, respectively and major adverse events at 0, 30 and 365 days 
were analyzed.
Results: Resuscitated STEMI patients (23 patients) and STEMI pa-
tients presenting at weekends (101 patients) and to lesser extent at 
night hours (100 patients) experienced more time delays than stable 
patients and those presenting at office hours. Median door-to-balloon 
time averaged 93 min in resuscitated, but 65 min in stable patients. 
Median door-to-balloon time at weekends and public holidays was 89 
min, but 68 min at office hours. Median time from hospital arrival to 
cathlab arrival at weekends and public holidays was 30 min, but 15 
min during office hours. Corresponding times for resuscitated patients 
was 45 and 15 min in stable patients. Of note, resuscitated patients 
were late presenters as regards time from symptoms onset to hospital 
arrival with a median time of 180 min compared to 155 min in stable 
patients. Median total ischemic time was 225 min for all patients, 223 
min at day hours, 239 at night hours, 244 min at weekends, 233 min 
at office days, 220 min in stable patients and 273 min in resuscitated 
patients. Patients with STEMI who arrived > 3 h after symptom onset 
had a higher rate of myocardial infarction (MI) at 1 year (1.6% vs. 9% 
in < 3 h; P = 0.008). Furthermore, STEMI patients who had a delay 
of > 1 h from cathlab arrival to first balloon inflation had a higher 
rate of in hospital reinfarction at 0 day (0.6% vs. 0% in < 1 h; P = 
0.007), MI at 30 days (0.8% vs. 0% in < 1 h; P = 0.001) and MI at 1 
year (1.4% vs. 1.1% in < 1 h; P = 0.012). Similarly, in these patients, 
cardiac deaths at 0 day (0.8% vs. 0.6% in < 1 h; P = 0.035) and at 30 
days (0.8% vs. 0.6% in < 1 h; P = 0.035) were higher as were major 
adverse cardiovascular events (MACCE) at 0 day (1.4% vs. 0.8% in 
< 1 h; P = 0.004).
Conclusion: Resuscitated STEMI patients and those presenting at 
weekends and to lesser extent at night hours experienced more time 
delays and longer ischemic time than stable patients and those pre-
senting at office hours. In STEMI patients, any delay in treatment 
increased their risk of MACCE. Efforts should focus on improving 
patient’s awareness along with minimizing in-hospital transfer to the 
catheterization laboratory especially at weekends and in resuscitated 
patients.
Keywords: Time delay to angioplasty; Acute coronary syndromes; 
Basic and outcome difference according time delays
Introduction
There is general consensus that proper timing of reperfusion 
therapy is very critical in the management of ST-segment 
elevation myocardial infarction (STEMI) patients, with the 
greatest benefit (i.e. salvage of the viable myocardium) seen 
in those undergoing reperfusion therapy within the first 2 - 3 
h of symptom onset [1, 2]. Current treatment strategies aim to 
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provide optimal care, while minimizing delays in order to im-
prove clinical outcomes. However, there still remains a wide 
range of logistic problems including patient delays and in-
hospital transfer which can render treatment goals unachiev-
able. Reduction of first-medical-contact-to-balloon time relies 
on efficient coordination of care between first medical contact 
or referral hospitals, the emergency medical service and the 
receiving hospitals. It is estimated that about two-thirds of pa-
tients achieve a guideline-recommended overall first-hospital-
door-to-balloon time of 120 min. It has been recommended 
that in patients referred to or presenting to percutaneous coro-
nary intervention (PCI)-capable centers, door-to-balloon time 
should be less than 60 min. On the other hand, in order to 
shorten reperfusion delays and lower in-hospital mortality, 
transfer from a non-PCI-capable center is advisable to occur 
within 30 min, which is normally referred to as door-in-to-
door-out time.
Methods
Study population
The prospective multi-center Special Program University 
Medicine (SPUM) - ACS Biomarker cohort (ClinicalTrials.
gov number, NCT01000701) recruited 2,200 patients who 
were referred for coronary angiography with a diagnosis 
of acute coronary syndrome (ACS) to one of the participat-
ing Swiss University Hospitals (Zurich, Bern, Lausanne, and 
Geneva) between December 2009 and October 2012. It com-
prised consecutive recruitment and follow-up performed at 30 
days (phone call) and 1 year (clinical visit). Female and male 
patients aged 18 years or older presenting within 5 days after 
pain onset with the main diagnosis of STEMI, non-ST-eleva-
tion myocardial infarction (NSTEMI) or unstable angina (UA) 
were included.
Within this consortium, a centralized electronic database 
was implemented providing comprehensive information on 
all patients. All adverse events occurring within 365 days 
after the index ACS event were ascertained at 30 days (tel-
ephone visit) and 1 year (clinical visit) and adjudicated by 
an independent adjudication committee consisting of three 
experienced cardiologists (Lukas Kappenberger, MD, Laus-
anne; TizianoMoccetti, MD, Lugano; Mathias E. Pfisterer, 
Basel, chair). In the current study, only patients recruited at 
the University Hospital Zurich were analyzed. The study was 
approved by the local ethics committee and all patients gave 
informed consent.
Patient selection
Included patients had symptoms compatible with angina pec-
toris (chest pain and dyspnea) and fulfilled at least one of the 
following criteria: 1) electrocardiogram (ECG) changes such 
as persistent ST-segment elevation or depression, T-inver-
sion or dynamic ECG changes, new left bundle branch block 
(LBBB); 2) evidence of positive (predominantly convention-
al) troponin by local laboratory reference values with a rise 
and/or fall in serial troponin levels; 3) known coronary artery 
disease (CAD), specified as status after myocardial infarction 
(MI), previous PCI or newly documented ≥ 50% stenosis of 
an epicardial coronary artery during the initial catheterization. 
Exclusion criteria comprised referral to either coronary artery 
bypass graft (CABG) or medical management after comple-
tion of the coronary angiogram, severe physical disability, and 
inability to comprehend study or less than 1 year of life expec-
tancy for non-cardiac reasons.
Endpoint definitions
All-cause mortality included cardiac, vascular and non-cardi-
ovascular causes of death. Cerebrovascular events comprised 
stroke or transient ischemic attack; repeat revascularization in-
cluded any repeat coronary revascularization (target and non-
target vessel). MI was defined based on the universal definition 
including peri-procedural MI in patients with UA [3].
Study endpoints
The primary endpoint of our study was adjudicated all-cause 
mortality in hospital, at 1-month and 1-year follow-ups. The 
secondary endpoints were major adverse cardiovascular events 
(MACCE), defined as a composite of all-cause mortality, cere-
brovascular event, any repeat revascularization and MI in hos-
pital (reinfarction) at 1 month and 1 year, and stent thrombosis 
in hospital, at 1 month and 1 year follow-ups.
Time intervals
For all patients, four time intervals were determined: 1) time 
from symptoms onset to hospital arrival: it is well known that 
the greatest benefit (i.e. salvage of the viable myocardium) is 
seen in those undergoing reperfusion therapy within the first 
2 - 3 h of symptom onset [1, 2, 4, 5], so we divided our patients 
in two groups (within 3 h or longer than 3 h); 2) time from 
hospital arrival to arrival in the catheterization laboratory: we 
construct it as stated by last AHA recommendation for STEMI 
system of care 2016 that considered maximum of 30 min for 
cathlab team to be ready from STEMI activation call (within 
30 min or after 30 min); 3) time from hospital arrival to first 
balloon inflation as it is stated by last ESC and AHA guidelines 
to be within 90 min as a maximum (we divided patients to two 
groups door-to-balloon time within 90 min or after 90 min); 
and 4) time from arrival in the catheterization laboratory to 
first balloon inflation (within 60 min and after 60 min), in ad-
dition to total ischemic time in minutes in relation to time of 
presentation and resuscitation.
Statistical analysis
All continuous variables were statistically described in terms 
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of median values as data were not normally distributed; cat-
egorical variables were presented as frequency (percentages) 
and were compared using Chi-square test. P values were used 
to describe significance. Statistical significance was set as a P 
value < 0.05. All statistical calculations were done using Sta-
tistical Package for Social Sciences (SPSS for Windows) soft-
ware (version 20.0, SPSS Inc., Chicago, IL, USA).
Results
Type of ACS
A total of 357 consecutive STEMI patients from Zurich en-
rolled in the prospective Special Program University Medicine 
ACS (SPUM-ACS) cohort were included.
Baseline characteristics
Their mean age was 62.3 years (range: 32 - 91.6 years), 81% 
were males, 43.4% were current smokers, 66.4% had hyper-
cholesterolemia, 54.3% were hypertensive and 15.1% diabet-
ics. A positive family history for CAD was noted in 21.6% and 
8.1% had a previous MI, 9% had undergone PCI previously 
and 2.5% CABG. Of the patients, 2.2% had a history of previ-
ous stroke. At entry, 8.9% of the patients had been resuscitated 
(Table 1).
Clinical outcomes
Overall mortality was 1.7% at day 0, still 1.7% at 30 days and 
3.6% at 1 year, while cardiac death was 1.4% at day 0, re-
mained at 1.4% at 30 days and was 2.2% at 1 year. MACCE 
were 2.2% at day 0, 3.6% at 30 days and 7.8% at 1 year. The 
percentage of those with recurrent MI was 0.6% at day 0 (in 
hospital reinfarction), 0.8% at 30 days and 2.5% at 1 year, 
while repeat revascularization was 0.8% at day 0, 2.0% at 30 
days and 5.3% at 1 year. Acute stent thrombosis occurred in 
0.3% at day 0, in 0.8% at 30 days and in 1.4% at 1 year. Major 
bleeding occurred in 5.6% at day 0, in 6.4% at 30 days and in 
9.2% at 1 year. Patients who arrived > 3 h from onset of symp-
toms had a higher rate of MI at 1 year (1.4% vs. 8% in < 3 h; P 
= 0.008). Further, patients in whom a first balloon inflation oc-
curred > 1 h after arrival in the catheterization laboratory had 
a higher rate of recurrent MI at day 0 (0.6% vs. 0% in < 1 h; P 
= 0.007), at 30 days (0.8% vs. 0% in < 1 h; P = 0.001) and at 1 
year (1.4% vs. 1.1% in < 1 h; P = 0.012) (Table 2).
Time delays
The overall delay
Median time from symptom onset to arrival at the hospital was 
156 min. Of the patients, 57.4% arrived within 3 h and 42.6% 
after 3 h. Median time from hospital arrival to catheterization 
laboratory arrival was 20 min. Of the patients, 59.4% arrived 
within 30 min and 40.6% after 30 min. Median time from hos-
pital arrival to first balloon inflation (door-to-balloon time) 
was 69 min; 63.3% of the patients were treated within 90 min 
and 36.7% after 90 min. Finally, median time from catheteri-
zation laboratory arrival to first balloon inflation was 36 min; 
78.4% of the patients achieved within 60 min and 21.6% after 
60 min (Figs. 1 and 2).
Delays and patient characteristics
Patients with history of a previous MI or PCI had a shorter 
time from symptoms onset to hospital arrival (P = 0.004).
Delays and time and day of presentation
We further found that patients presenting at night time (n = 
100) had slightly longer median door-to-balloon time (74 
min) than those arriving at office hours (68 min) at office 
hours, while the former group required more than 90 min in 
42% of the patients, and in the latter only 33.9% had such 
a long door-to-balloon time (P = 0.012). Furthermore, over-
all median door-to-balloon time was 89 min at weekends and 
public holidays (n = 101), but 68 min during office hours. 
Again, door-to-balloon time was more than 90 min in 47.5% 
of patients presenting at such days, but only 31.7% of those 
arriving during office hours (P = 0.023). Median time from 
hospital arrival to cathlab during night hours was 20 min and 
similar to office hours. During night hours, 39.8% of patients 
took more than 30 min versus 40.9% of those arriving dur-
ing day hours (P = 0.843). The median time at weekends and 
public holidays was 30 and 15 min during office hours with 
48.6% of the patients arriving after 30 min at weekends and 
public holidays and 37.5% during office hours (P = 0.034). 
Lastly as regards median time from cathlab arrival to first bal-
loon inflation, this averaged 37 min during office hours, but 
36 min at night time, and 35 min at weekends. Time from 
cathlab arrival to first balloon inflation of more than 1 h oc-
curred in 20.6% of patients arriving at weekends and in 22% 
in those presenting during office hours (P = 0.782). The corre-
sponding values for at night time and office hours were 22.9% 
and 20.9%, respectively (P = 0.685).
Time delays in resuscitated patients
A total of 23 resuscitated STEMI patients, of which 16 patients 
had received out-of-hospital resuscitation and seven patients 
with in-hospital resuscitation, had a median time from symp-
toms onset to hospital arrival of 188 min as compared to 155 
min in non-resuscitated patients. Median door-to-balloon time 
was 93 min, but 65 min in non-resuscitated patients. Median 
time from hospital arrival to first balloon inflation averaged 45 
min, but only 15 min in non-resuscitated patients. Median time 
from cathlab arrival to first balloon inflation was 44 min, but 
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only 36 min in non-resuscitated patients.
Time delays and infarct size
Late arrivals from symptoms onset to hospital entry had sig-
nificantly higher peak CK-MB and higher high-sensitivity 
troponin T levels than early arrivals. Similarly, patients with 
prolonged time from hospital to arrival to the catheterization 
laboratory, longer door-to-balloon time or time from catheteri-
zation laboratory arrival to first balloon inflation had signifi-
cantly higher levels of peak troponin T levels than early ar-
rivals.
Total ischemic time
Median total ischemic time was longer for patients presenting 
Figure 1. Mean time intervals in minutes to primary PCI in STEMI in different patient groups.
Figure 2. Percentage of patients managed earlier in relation to patients presentation.
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at weekends, at night hours and resuscitated patients, was 225 
min for all patients, 223 min at day hours, 239 min at night 
hours, 244 min at weekends, 233 min at office days, 220 min 
in stable patients and 273 min in resuscitated patients.
Discussion
In current study, we found that STEMI patients who arrived > 
3 h from onset of symptoms had a significantly higher percent-
age of MI at 1-year follow-up; furthermore, patients who had a 
delay of > 1 h from arrival at the catheterization laboratory to 
first balloon inflation had a higher rate of recurrent MI at day 
0, at 30 days and at 1 year as well as a higher rate of cardiac 
deaths at these time points. Time delays in STEMI patients 
included patient’s delay along with delays in pre-hospital 
management, in-hospital transportation to the catheterization 
laboratory and within the catheterization laboratory until a first 
balloon inflation. STEMI patients presenting at weekends or 
public holidays and to a lesser extent those arriving at night 
time exhibited more time delays and longer total ischemic time 
than those presenting at daytime or office hours; this finding 
agrees with recently published Japanese study 2017 which 
documented off hours presentation as a cause of delay to pri-
mary PCI in multicenter registry [6]. Although overall the de-
lays were only in a minority of patients longer than the time 
periods recommended in current guidelines, our findings nev-
ertheless show that even in experienced tertiary centers current 
real world practice should be further improved, indeed patient 
delays might be shorter with a broader knowledge about the 
clinical presentation of infarction in the population as 85% 
of our patients experienced the first event upon presentation; 
however, most of them (80%) had any or several cardiovascu-
lar risk factors, physicians managing such patients must there-
fore inform them better about how and when to react in case of 
acute chest pain and/or dyspnea in order to shorten symptom 
onset to arrival time. In-hospital delays do require organiza-
tional measures both in the emergency department, transport 
services as well as in the catheterization laboratory in order to 
further shorten door-to-balloon-time. Previous studies mostly 
focused on symptom-to-PCI delays for example data from two 
small German studies involving only 264 patients reported 
no reduction in infarct size with primary PCI with decreasing 
symptom-to-PCI duration [7]. However, half of the patients 
in those studies had been treated by thrombolytic therapy. In 
line with our findings, other studies have found reduction in 
mortality with decreasing symptom-to-PCI delays [8, 9]. How-
ever, other studies have shown limited or no effect on mortal-
ity with shorter symptom-to-PCI delays [10-12]. The first of 
these two studies [11] considered 2 h as ideal door-to-balloon 
time. In a second study [12], only percutaneous transluminal 
coronary angioplasty was performed and there were no dif-
ferences in 1- or 6-month mortality by time to reperfusion 
(6-month mortality: < 2 h (5.5%), 2 to < 4 h (4.6%), 4 to < 6 h 
(4.5%), > 6 h (4.2%), P = 0.97). There were also no differences 
in other clinical outcomes by time to reperfusion, except that 
reinfarction and infarct artery reocclusion at 6 months were 
more frequent with later reperfusion. Doing PTCA only and 
only follow-up for short period (only 6 months) explain the 
different results compared to our study. Thus, previous studies 
using symptom-to-PCI as a primary measure of time to treat-
ment have been inconsistent with each other both regarding 
infarct size and clinical outcomes [13-15]. Several other stud-
ies have focused mainly on door-to-balloon time and showed 
convincing data regarding improved clinical outcomes with 
decreasing door-to-balloon times [11, 12, 16]. However, door-
to-balloon time only focuses on the final part of the health care 
chain leaving out critical care elements where improvements 
could be achieved by appropriate measures. Our findings thus 
reinforce the current European Society of Cardiology guide-
lines on STEMI that state that a delay of 60 min or less from 
first medical contact to PCI is desirable, and that a timing of 
90 min should be considered the upper limit [1]. Finally, an 
important lesson of the current study is that we also need to 
work on in-hospital delays either from hospital arrival to the 
catheterization laboratory or within catheterization laboratory 
and to provide a clear definition for ideal catheterization labo-
ratory arrival to first-balloon-inflation time that reflects time 
delays within catheterization laboratory and hospital arrival to 
cathlab arrival time that reflects time in hospital delays.
Study limitations
Our study demonstrates results from a single center prospec-
tive cohort with retrospective data analysis with a moderate 
number of patients which in turn could benefit from validation 
in a larger population as part of a prospective trial. One limita-
tion in our study comes from using the 2007 definition of MI 
which could have led to over diagnosis of MI.
Incremental value
In spite of gradual improvement of time to primary PCI in the 
last few years, there remain some factors that lead to delays 
in door-to-balloon time even in tertiary centers with a large 
case load as the current department. Importantly, we show that 
delay is also related to the time and day of presentation, in par-
ticular at weekends and public holidays stressing the need for 
logistic improvements particularly during such time periods. 
Furthermore, to reduce symptom onset to arrival times, it ap-
pears important that public education programmes are imple-
mented to further reduce patient delays, while organizational 
measures should be considered to shorten time delays within 
the hospital and the catheterization laboratory, especially at 
weekend and night time.
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